Northwest Biotherapeutics

Showcase Sponsor

Northwest Biotherapeutics is focused on developing personalized, non-toxic, cost-effective immunotherapy products to treat cancers more effectively than current treatments.  We have a broad platform technology for DCVax® dendritic cell-based vaccines, with clinical trials in the US, Canada, and Europe.  Our lead program is a 348-patient Phase III trial with DCVax-L for operable, newly-diagnosed Glioblastoma multiforme (GBM) brain cancer.  Our second product, DCVax-Direct, is in Phase I/II trials for all types of inoperable solid tumor cancers.